CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Germany's Merck raises 2026 guidance for third time

By Reuters News

FRANKFURT, Nov 12 (Reuters) - German drugmaker Merck KGaA MRCG.DE on Thursday raised its 2026 core profit guidance for the third time this year, helped by better underlying performance, foreign exchange effects and the acquisition of US firm Bio-Techne.

The diversified, family-controlled group said it expects adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) in a range of €6.2 billion to €6.4 billion, up from previous guidance of €5.9 billion to €6.3 billion.

Here are more details:

  • Merck now expects full-year revenue of between €21.5 billion and €21.9 billion (previously: €21-21.8 billion).

  • In Q3, net revenue grew by 5.8% on the year to €5.6 billion while EBITDA was up 0.8% to €1.7 billion.

  • "Our third-quarter performance underscores the strength of our integrated business model with our strong position in attractive growth markets, especially biomanufacturing, discovery and development across the life sciences value chain, semiconductor manufacturing that supports AI and advanced nodes, as well as targeted specialty and rare diseases," CEO Kai Beckmann said.

  • As a supplier to the semiconductor industry, Merck manufactures specialty materials and chemical solutions used to produce advanced microchips that underpin AI applications and data centres.

  • In June, Merck boosted its Life Science unit, which makes drug research and manufacturing tools, by striking an $11.3 billion deal to buy Bio-Techne, its biggest transaction in more than a decade.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.